

Dr. Doug Manion joins Board of Celleron Therapeutics

Oxford 24th May 2017; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced today that Doug Manion M.D., FRCP(C) is joining the Board of Directors as a Non Executive Director, with immediate effect. Dr. Manion has more than 25 years experience both as a physician and in the pharmaceutical industry and most recently served as the Senior Vice President, Head of Specialty Development and Head of China and Japan R&D for Bristol Myers Squibb.

"I am very pleased to welcome Doug to the Board of Celleron at this critical time, as we advance CXD101 as monotherapy and in combination with immune-oncology agents. Doug has years of valuable experience in the pharmaceutical industry and in providing leadership in R&D. As a Board member, he will be an active contributor to our growth and will be instrumental as we build the portfolio to achieve our vision of advancing effective and safe medicines that address the unmet medical needs of cancer patients," said Nick La Thangue Chief Executive Officer of Celleron.

Prior to leading Specialty Development and heading R&D in China and Japan from August 2014, Dr. Manion served in a number of leadership roles at BMS in virology, neurology and oncology since joining in May of 2005. Before that, he served as the Vice President of Clinical Development and Medical Affairs for HIV/AIDS for Glaxo Smith Kline and, prior to that, Medical Director for virology for Dupont Pharmaceuticals from July 1997 to September 2001. Dr. Manion received a B.A Sc in Civil Engineering followed by qualification with a Doctorate in Medicine from the University of Ottawa in Canada in 1987. He is Board Certified in Internal Medicine, completed an Infectious Diseases Clinical Fellowship from the University of Ottawa and completed a post-doctoral research fellowship at Massachusetts General Hospital, Harvard Medical School.

"I am delighted to be joining Celleron as a member of its Board at this exciting time and to be helping the team deliver on its vision for the future," said Dr. Manion. "In my new role as a Non Executive Director with the Company, I am keen to contribute to the mission of realising a future in which cancer patients live longer and better lives than previously possible, and both CXD101 and CXD201 have great potential to deliver these benefits"

About Celleron Therapeutics

Celleron Therapeutics, based on the Oxford Science Park, UK, is a drug development company focussed on precision medicine for cancer. It is a spin-out of Oxford University and has secured a number of exclusive licence agreements with pharmaceutical companies, including Astra Zeneca. Celleron's precision medicine approach is supported by a companion diagnostic biomarker platform, which allows new drugs to be tailored to responsive tumours. Celleron has two Phase 2 clinical assets: CXD101 is a novel dual mechanism HDAC inhibitor which has unique immuno-modulatory effects in tumour cells, and CXD201 represents a new type of topoisomerase inhibitor.